About: http://webisa.webdatacommons.org/219574873

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	Additionally, the FDA has not yet developed a robust biosimilar approval pathway, raising questions regarding the types of studies (pre-clinical and clinical) that would be required to gain FDA approval.
http://www.w3.org/ns/prov#wasQuotedFrom	nccn.org